Home Blog Page 2291

TWOPAGES Unveils 2025 Autumn/Winter Home Trends, Blending Texture, Heritage, and Functionality

SPOKANE, Wash., Sept. 25, 2025 /PRNewswire/ — As the demand for elevated living spaces continues to grow, TWOPAGES Curtains, a provider of high-quality, stylish custom window treatments, has introduced its 2025 Autumn/Winter interior trends, setting the tone for the season with three guiding themes: Warm Minimalism × Layered Neutrals, Heritage Pattern × Modern Collaboration, and Luxe Comfort × Functional Elegance.

The first trend, Warm Minimalism × Layered Neutrals, embraces earthy tones and natural materials to create interiors that feel restorative yet sophisticated. The Jawara Luxury Linen Cotton Curtain embodies this spirit, offering a heavyweight linen-cotton blend with a refined slubbed texture. Its breathable, eco-conscious composition makes it as functional as it is aesthetic. The Linnea Linen Cotton Embroidered Curtain takes this further, weaving delicate leaf motifs across soft fabric to add subtle dimensions to neutral interiors. For those seeking warmth and substance, the Karin Pure Wool Curtain provides natural insulation, balancing temperature while enhancing privacy with its dense, midweight wool. Completing this grouping, the Veda Luster Cotton Velour Drapery brings a dramatic touch through its high-shine velour finish, transforming everyday spaces into refined sanctuaries.

Image Source: TWOPAGES Jawara Luxury Linen Cotton Curtain
Image Source: TWOPAGES Jawara Luxury Linen Cotton Curtain

While minimalism speaks to calm and comfort, TWOPAGES also explores the power of heritage. The second theme, Heritage Pattern × Modern Collaboration, draws on classic motifs and partnerships with contemporary designers to bring timeless patterns into today’s homes. The Sara Le x TWOPAGES collection illustrates how earthy tones and neutral palettes can achieve quiet sophistication, while remaining approachable in design and function. Similarly, Canadian designer Britt Bengoechea collaborates with TWOPAGES on a floral collection inspired by European countryside aesthetics. These patterns, reinterpreted with modern sensibility, bring depth and warmth without overwhelming contemporary interiors. Among standalone designs, the Holly Country Floral Drapery pleated curtain adds bohemian character with a curated mix of artistic floral prints, offering both softness and practicality. The Celia Striped Plaid Collection introduces a casual, rustic note, balancing timeless stripes and plaids with everyday durability. Collectively, these designs demonstrate how tradition and modernity can be layered to create homes that feel familiar yet fresh.

Image Source: TWOPAGES Sara Le Print Linen Drapery
Image Source: TWOPAGES Sara Le Print Linen Drapery

The third trend, Luxe Comfort × Functional Elegance, responds to a growing preference for fabrics that are both indulgent and highly practical. Velvet takes center stage here, serving as both a visual and tactile highlight. The Birkin Velvet Curtain exemplifies this with plush polyester velvet that cascades in structured folds, delivering both dramatic presence and functional benefits such as light blocking and thermal insulation. Expanding on this idea, the Amy Switzer x TWOPAGES collaboration reimagines velvet through a contemporary lens, introducing deep jewel tones, painterly motifs, and ombré layering. This collection highlights how velvet can shift from vintage charm to modern artistry without losing its sense of luxury. For interiors requiring heightened performance, the Tavis Premium Velvet Curtain combines dense velvet with exceptional sound-dampening and insulating properties, making it as technically advanced as it is visually appealing.

Image Source: TWOPAGES Amy Switzer Printed Velvet Pleated Drapery
Image Source: TWOPAGES Amy Switzer Printed Velvet Pleated Drapery

Taken together, these three design directions highlight TWOPAGES’s ongoing exploration of how materials, craftsmanship, and aesthetic sensibilities can adapt to changing consumer lifestyles. While warm neutrals offer a retreat into natural calm, heritage-inspired patterns connect past and present, and velvet-driven elegance bridges comfort with function. Each

theme responds to the evolving expectation that interiors must not only look elevated but also support everyday living with durability and adaptability.

At the heart of TWOPAGES’s seasonal outlook lies a consistent brand philosophy. Rooted in simplicity, a neutral lifestyle, and uncompromising quality, the brand seeks to fuse artistry with function. The result is a portfolio of products that transform homes into spaces where texture, beauty, and comfort coexist. In the 2025 Autumn/Winter season, TWOPAGES once again demonstrates that luxury in interiors is no longer about excess, but about creating an atmosphere where aesthetic refinement and practical performance work hand in hand.

About TWOPAGES Curtains

Founded in 2015 with a mission to revolutionize the window treatment industry, TWOPAGES Curtains has become a leader in providing high-quality, customizable solutions that simplify the shopping experience. With a focus on transparency, innovation, and customer satisfaction, TWOPAGES continues to set the standard for excellence in the industry.

Stay updated with TWOPAGES’ latest information, please visit:

Website: https://twopagescurtains.com/

Instagram: https://www.instagram.com/twopagescurtains/    

 

Boldyn Networks raises the roof at AO Arena Manchester with enhanced 5G fan experiences

O2 is the first UK mobile operator to join the 5G neutral host network at AO Arena Manchester  

LONDON, Sept. 25, 2025 /PRNewswire/ — Boldyn Networks (Boldyn) is providing advanced 5G connectivity at the iconic AO Arena Manchester, one of the UK’s busiest entertainment venues and one of the largest indoor sporting arenas in Europe. With a rollout of its innovative neutral host 5G Distributed Antenna System (DAS), Boldyn is laying the groundwork for all UK mobile operators to provide uninterrupted, high-speed 5G coverage at the venue. And O2 customers are the first to benefit from unforgettable entertainment moments, now enhanced by seamless connectivity.

Fans at AO Arena Manchester
Fans at AO Arena Manchester

The network rollout at AO Arena Manchester builds on Boldyn’s ongoing partnership with Legends Global, and follows recent deployments at other major venues, including the first direct bank arena in Leeds and several deployments at leading venues globally. It marks another step in Boldyn and Legends Global’s mission to redefine fan connectivity experiences worldwide.

The 23,000 capacity AO Arena Manchester attracts over 1.2 million visitors each year. With the new connectivity solution in place, fans can expect improved venue accessibility, the availability of fast mobile ordering of food and drinks, ultra-HD livestreaming at four times the current speed, and a reliable connection that ensures they can stay connected with friends throughout the event.

Paul Osborne, CCO UK & Ireland at Boldyn Networks, added: “We’re proud to partner with Legends Global to build the most interconnected sports and entertainment venues around the world. Advanced 5G connectivity infrastructure is empowering fans and venue staff alike to access next‑gen digital services, and we’re supporting all UK mobile operators in delivering on that ambition. Our deployments continue to demonstrate the power of shared infrastructure, and we’re thrilled to be working with O2 to elevate the connected experience for its customers at this iconic UK venue.”

Dr Robert Joyce, Director of Mobile Access Engineering, at O2 said: “Delivering unique live experiences is a huge part of our identity at O2. Wherever our customers go, we’re committed to providing an exceptional, reliable mobile experience that lets them share highlights of the event and stay connected in the busiest locations. Given our heritage in live entertainment, it makes sense that our customers would be the first to benefit from seamless connectivity at AO Arena Manchester.”  

Boldyn’s innovative, neutral host 5G DAS solution at AO Arena Manchester supports all UK mobile operators, ensuring consistent, high-performance coverage for every fan, staff member, and vendor. This shared infrastructure model enables seamless digital engagement and operational efficiency across some of the world’s busiest entertainment environments.

Learn more at www.boldyn.com

INEOS Styrolution marks milestone with first commercial delivery of recycled styrene monomer from Indaver

  • Recycled styrene monomer produced via depolymerisation now delivered at scale
  • Enables high-quality styrenics, including for food-grade and medical applications
  • Adds chemically recycled material to our portfolio alongside mechanically recycled and bio-attributed products

FRANKFURT, Germany, Sept. 25, 2025 /PRNewswire/ — The first truckloads of recycled styrene monomer (SM) have arrived at INEOS Styrolution’s Antwerp site. The material was supplied by Indaver from its new depolymerisation plant, the first facility in Europe dedicated to polystyrene recycling, inaugurated on 25th September 2025. Also located in Antwerp, this local set-up keeps the supply chain short and sustainable.

Aerial view of Indaver Plastics2Chemicals Plant © Indaver
Aerial view of Indaver Plastics2Chemicals Plant © Indaver

This is the first commercial-scale delivery of recycled SM in Europe. It enables the production of high-quality polystyrene and other styrenics, including for food-grade, transparent, and medical applications.

This recycled feedstock adds to INEOS Styrolution’s sustainable styrenics portfolio, which already comprises mechanically recycled and bio-attributed grades, and demonstrates the company’s ability to deploy multiple recycling technologies for different waste streams.

“We are pleased that we can now offer styrenics from depolymerisation at market scale”, remarks Rob Buntinx, President EMEA, INEOS Styrolution. “This gives our customers more sustainable options to lower their environmental footprint without compromising product quality or performance.”

“With Plastics2Chemicals (P2C), Indaver is pioneering in the circular economy and advanced chemical recycling. By converting hard-to-recycle plastics into virgin-quality feedstock such as styrene, we are closing the loop and offering a sustainable alternative to fossil resources”, states Erik Moerman, Sales and Development Director P2C. “Our in-house developed technology, combined with strategic partnerships and continuous innovation, enables us to deliver high-purity materials for demanding applications like food packaging − proving that circularity and performance can go hand in hand.”

This milestone highlights what sets polystyrene apart: it can be broken back down to its original monomer and rebuilt for high-value use. Depolymerisation is also more energy-efficient than other advanced recycling methods such as pyrolysis. It keeps the material in circulation, turning waste back into a valuable resource instead of landfill or litter.

Further information:

Depolymerisation is a chemical recycling process that breaks polystyrene down into its original building block styrene monomer, in contrast to mechanical recycling where plastic waste is physically processed back into pellets, without changing the basic chemical structure of the material. As the material is returned to the molecular level during depolymerisation, it enables the production of new styrenics with the same quality and properties as fossil-based products, including compliance with strict food-contact standards. Compared to conventional fossil-based production, depolymerisation avoids multiple resource-intensive steps, resulting in lower resource use and significantly reduced greenhouse gas emissions.

About INEOS Styrolution

INEOS Styrolution is the number one producer of high-performance styrenics, offering a broad portfolio that comprises styrene monomer, polystyrene, ABS, and advanced styrenics. The company delivers customised solutions for customers across automotive, healthcare, electronics, household, construction, packaging, toys, sports and leisure sectors. With more than 90 years of innovation in material science and 16 production sites worldwide, INEOS Styrolution combines global reach with local expertise to meet the evolving needs of its customers. This includes bringing safe, sustainable, and high-performing products to market and supporting their efforts toward meeting their sustainability targets.
INEOS Styrolution is fully owned by INEOS Group.

For further information, please visit: www.ineos.com/styrolution

Bambusa Therapeutics Announces Highly Positive Healthy Volunteer Results and First Atopic Dermatitis Patient Dosed in Phase I Trial of BBT001

BOSTON, Sept. 25, 2025 /PRNewswire/ — Bambusa Therapeutics, Inc. (Bambusa Therapeutics), a clinical-stage biotechnology company pioneering next-generation bispecific antibodies for immunology and inflammation, today announced two landmark achievements for its lead program, BBT001.

Last week, Bambusa Therapeutics unveiled highly positive results from the single ascending dose portion of its ongoing Phase I healthy volunteer study of BBT001 at the European Academy of Dermatology and Venereology (EADV) 2025.

The data demonstrated:

  • A favorable safety and tolerability profile across all dose levels with no dose-limiting adverse events.
  • A best-in-class pharmacokinetic profile (~33-day half-life), validating Bambusa’s half-life extension technology and supporting flexible dosing regimens.
  • Rapid, complete, and sustained IL-4Rα binding and pSTAT6 inhibition observed through Week 8+ following a single dose of BBT001.

IL4R binding and pSTAT6 inhibition
IL4R binding and pSTAT6 inhibition

  • An unprecedented, dose-dependent, rapid, deep, and sustained reduction in TARC levels after a single dose of BBT001, with potent suppression maintained through Week 8+.

TARC reduction
TARC reduction

“These results provide the first clinical evidence of BBT001’s potential to become a best-in-disease biologic in atopic dermatitis,” said Thang Ho, Ph.D., Senior Vice President of Development Sciences at Bambusa Therapeutics. “Despite low baseline TARC levels, we observed an unprecedented dose-dependent reduction in healthy volunteers, suggesting synergy between IL-4Rα and IL-31 inhibition. Given the strong correlation between TARC reduction and treatment efficacy in atopic dermatitis, these data give us confidence that BBT001 may deliver faster onset and deeper relief for patients across the Type 2 inflammatory skin disease spectrum.”

Today, Bambusa Therapeutics has achieved its next major milestone: the dosing of the first patient with moderate-to-severe atopic dermatitis in the Phase I clinical trial of BBT001.

“Achieving patient dosing within 16 months of company inception underscores our pace of execution and represents a powerful moment for Bambusa Therapeutics and the atopic dermatitis community.”, said Shanshan Xu, M.D., Ph.D., Founder & Chief Executive Officer of Bambusa Therapeutics. “With the trial now underway, we feel a deep responsibility to patients to accelerate development, generate proof-of-concept clinical data in patients, challenge and ultimately redefine the standard of care in atopic dermatitis.”

About the BBT001-001 Clinical Trial
BBT001-001 is a randomized, placebo-controlled, single- and multiple-ascending-dose study in healthy volunteers and adults with moderate to severe atopic dermatitis. The trial is evaluating safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics, and preliminary clinical activity. Patient enrollment is ongoing, with additional data expected in 2026.

About BBT001
BBT001 is Bambusa Therapeutics’ lead program and a first-in-class, multi-targeting, half-life extended bispecific antibody engineered to block both IL-4Rα and IL-31 signaling. By addressing type 2 inflammation and directly targeting the pathways that drive itch, BBT001 is designed to provide faster and more durable relief for patients with atopic dermatitis and other inflammatory skin diseases. The molecule has demonstrated a favorable safety profile and strong pharmacokinetics in healthy volunteers, supporting its advancement into patient studies.

About Bambusa Therapeutics, Inc.
Bambusa Therapeutics is a clinical-stage biotechnology company building a portfolio designed to transform care across a wide spectrum of chronic disease. Powered by an innovative antibody engineering platform enhanced with half-life extension and high-concentration subcutaneous delivery, the company’s vision is to deliver transformative medicines for patients across every stage of life, setting the pace for the next era of I&I therapeutics. Headquartered in Boston, Bambusa Therapeutics’ pipeline is designed to achieve best-in-disease impact across multiple therapeutic areas:

  • BBT001 is a first-in-class half-life extended bispecific antibody targeting IL-4Rα and IL-31, currently in Phase 1 clinical development for atopic dermatitis and other Type 2 inflammatory skin diseases.
  • BBT002 is a first-in-class half-life extended bispecific antibody targeting IL-4Rα and IL-5, in Phase 1 clinical development for Type 2 inflammatory disorders including COPD, asthma, and chronic rhinosinusitis with nasal polyps (CRSwNP).
  • BBT003 and BBT004 are preclinical programs focused on gastroenterology, including inflammatory bowel disease (IBD), and rheumatological diseases, respectively.

For more information, visit www.bambusatx.com.

 

YY Group Secures Five New Luxury Hotel Clients in Thailand

SINGAPORE, Sept. 25, 2025 /PRNewswire/ — YY Group Holding Limited (NASDAQ: YYGH) (“YY Group,” “YYGH,” or the “Company”), a global leader in on-demand workforce solutions and integrated facility management (IFM), today announced that its subsidiary, YY Circle Thailand, has secured contracts with five leading hotel clients; Hyatt, Sheraton, and three properties under Chatrium Hotels & Residences. These signings significantly expand the subsidiary’s hospitality portfolio and reinforce YY Group’s regional growth strategy.

Strategic Wins with Hyatt, Sheraton and Chatrium Hotels

Since being acquired by YY Group earlier this year, YY Circle Thailand has continued to build on its established client base, which already included leading names such as Central Group, CP All, Shangri-La, and Banyan Tree. The addition of Hyatt, Sheraton, and Chatrium further strengthens YY Group’s presence in Southeast Asia and is expected to contribute meaningfully to projected 2025 revenue from the Thai market.

These partnerships underscore YY Circle Thailand’s ability to attract internationally recognized hotel brands while leveraging its technology-enabled staffing and hotel services platform to enhance operational efficiency and deliver greater value to clients.

Chatrium Hotels & Residences

Chatrium Hotels & Residences is a renowned Thai hospitality group offering luxury hotels and serviced residences in Bangkok, Phuket, and other key destinations. Known for blending contemporary design with Thai cultural heritage, Chatrium delivers upscale accommodations and memorable guest experiences.

Growth Outlook & Strategic Vision

The signing of these five hotel clients represents a major milestone in YY Circle Thailand’s expansion. Management expects the subsidiary to play a significant role in YY Group’s revenue pipeline in 2025 and beyond, driven by growing demand for staffing, hotel operations support, and technology-enabled services.

“These new partnerships validate the strength of our platform and our ability to support top-tier hotels in Thailand,” said Mike Fu, Chief Executive Officer and Executive Director of YY Group Holding Limited. “We are excited to deepen relationships with global brands like Hyatt and Sheraton while strengthening ties with leading local players like Chatrium.”

Jirapat Haetanurak, Co-founder and Country Director of YY Circle Thailand, added, “Securing these five landmark hotel clients so soon after joining the YY Group family demonstrates the trust leading hospitality brands place in our team. By combining YY Circle Thailand’s local expertise with YY Group’s technology and resources, we are well-positioned to deliver even greater value to our partners and accelerate growth across the Thai market.”

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the Company’s expectations for the performance and contribution of newly secured hotel clients in Thailand, the growth potential of YY Circle Thailand, the Company’s revenue outlook, strategic initiatives, and regional expansion plans. These statements are based on the current expectations and beliefs of YY Group Holding Limited’s (“the Company”) management and are subject to a number of risks, uncertainties, and assumptions.

Factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statement include, but are not limited to: (i) the performance of newly onboarded hotel clients, including Hyatt, Sheraton, and Chatrium properties; (ii) the Company’s ability to successfully integrate and scale its services in Thailand; (iii) demand for staffing and operational support services in the hospitality sector; (iv) competition in the Southeast Asian hospitality and labor solutions markets; (v) broader economic or industry conditions affecting the travel and tourism sector; and (vi) other risks and uncertainties disclosed in the Company’s filings with the U.S. Securities and Exchange Commission.

In some cases, forward-looking statements can be identified by terminology such as “may,” “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” or other similar expressions. These statements are made only as of the date of this press release. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.

About YY Holdings Limited

YY Group Holding Limited (Nasdaq: YYGH) is a Singapore-headquartered, technology-enabled platform providing flexible, scalable workforce solutions and integrated facility management (IFM) services across Asia and beyond. The Group operates through two core verticals: on-demand staffing and IFM, delivering agile, reliable support to industries such as hospitality, logistics, retail, and healthcare.

Leveraging proprietary digital platforms and IoT-driven systems, YY Group enables clients to meet fluctuating labor demands and maintain high-performance environments. In addition to its core operations in Singapore and Malaysia, the Group maintains a growing presence in Asia, Europe, Africa, Oceania and the Middle East.

Listed on the Nasdaq Capital Market, YY Group is committed to service excellence, operational innovation, and long-term value creation for clients and shareholders.

For more information on the Company, please log on to https://yygroupholding.com/.

Investor Contact
Phua Zhi Yong, Chief Financial Officer
YY Group
enquiries@yygroupholding.com 

Mark Niu, Chief Strategy Officer,
YY Group
mark.niu@yygroupholding.com 

Milliken Assure™ Moisture Barrier Wins 2025 R&D 100 Award

Diversified global manufacturer recognized for redefining moisture barrier performance in firefighter turnout gear

SPARTANBURG, S.C., Sept. 25, 2025 /PRNewswire/ — Milliken & Company is proud to announce that its Milliken Assure™ moisture barrier, the first non-PFAS, non-halogenated, UL-certified flame-resistant moisture barrier for firefighter turnout gear in North America, has been named a winner of the 2025 R&D 100 Awards. This recognition places Assure among the year’s most innovative technologies and highlights Milliken’s commitment to solving complex performance challenges through materials science.

Milliken Assure™ moisture barrier, the first non-PFAS, non-halogenated, UL-certified flame-resistant moisture barrier for firefighter turnout gear in North America, has been named a winner of the 2025 R&D 100 Awards.
Milliken Assure™ moisture barrier, the first non-PFAS, non-halogenated, UL-certified flame-resistant moisture barrier for firefighter turnout gear in North America, has been named a winner of the 2025 R&D 100 Awards.

“We are honored to receive an R&D 100 Award for Assure,” said Halsey Cook, president and CEO of Milliken. “This recognition reflects the ingenuity of our team and our dedication to solving real-world challenges through materials science and innovation.”

Assure was selected for its pioneering design that eliminates per- and polyfluoroalkyl substances (PFAS) and halogenated flame retardants—two chemistries long used in moisture barriers—while meeting the rigorous demands of structural firefighting. Certified to both NFPA 1971-2018 and NFPA 1970-2025 standards, Assure delivers heat, water, and chemical resistance without relying on added PFAS or halogenated flame retardants.

Assure’s lightweight and breathable construction helps firefighters perform under pressure while meeting rigorous safety benchmarks. It joins Milliken’s growing portfolio of non-PFAS fire service fabrics, offering departments across the country advanced solutions as they evaluate and upgrade their turnout gear. Assure was developed by a cross-functional team of engineers, scientists, and product design experts, reflecting Milliken’s collaborative approach to innovation.

“Assure was born from listening to the fire service and recognizing a challenge that had gone unanswered for too long,” said Marcio Manique, SVP and managing director of Milliken’s apparel business. “This R&D 100 Award is more than recognition—it’s proof that Assure is setting a new standard and making a real difference for those who protect us every day.”

The R&D 100 Awards, often referred to as the “Oscars of Innovation,” honor the most impactful new products of the year across science and technology. Milliken has previously received R&D 100 recognition for innovations in textiles and specialty chemicals.

About Milliken  
Milliken & Company is a global manufacturing leader whose focus on materials science delivers tomorrow’s breakthroughs today. From industry-leading molecules to sustainable innovations, Milliken creates products that enhance people’s lives and deliver solutions for its customers and communities. Drawing on thousands of patents and a portfolio with applications across the textile, flooring, chemical and healthcare businesses, the company harnesses a shared sense of integrity and excellence to positively impact the world for generations. Discover more about Milliken’s curious minds and inspired solutions at milliken.com and on Facebook, Instagram, and LinkedIn.

 

 

Trench Group acquires Australian technology firm H Nu

Next-Generation Optical Instrument Transformers to Strengthen HVDC Leadership

BERLIN, Sept. 25, 2025 /PRNewswire/ — Trench Group continues to advance its global growth strategy and commitment to innovation. Building on recent investments in new manufacturing sites and upgrades to existing facilities, the company has now acquired the Australian technology firm H Nu, expanding its portfolio with cutting-edge fiber-optic instrument transformer technology. This acquisition enables Trench Group to deliver ultra-fast response times in power transmission operations. While the technology supports all transmission types, it offers particular advantages for High Voltage Direct Current (HVDC) systems.

Initial fiber-optic units have already been successfully deployed in transmission grids worldwide. Trench is collaborating with leading system suppliers to qualify this technology as a future standard for high-voltage measurement – laying the groundwork for rapid scale-up and series production.

The integration of H Nu reinforces Trench Group’s position as a global leader in innovation and technology for high-voltage transmission components. H Nu’s expertise in fiber-optic measurement complements Trench’s existing capabilities.

“This marks Trench Group’s first acquisition. H Nu’s technology will benefit from our leadership in HVAC and HVDC systems and our global market reach,” says Dr. Bahadir Basdere, CEO of Trench Group. “We’re excited to offer our customers the latest advancements in flexible, fast-reacting systems and power quality solutions – this is critical as global power grids grow increasingly complex.”

This acquisition underscores Trench Group’s role as a reliable, forward-looking partner for system-critical power transmission solutions.

About Trench Group:

Trench Group is a leading global supplier of components and systems for high-voltage power transmission. Headquartered in Berlin and with more than 100 years of experience, the company is a leader in the high-voltage solutions portfolio. With its product groups bushings, coils, and instrument transformers, the company is a systemically important player in the field of energy transition and sustainable energy for the future. These intelligent and technologically sophisticated components and systems are used for measurement, protection, and connection within the power grid. The Trench Group operates globally with more than 2,800 employees at nine factory locations and four regional sales hubs. 

For more information, visit www.trench-group.com.

– Picture is available at AP

Media contact:
Günther Hörbst
Vice President Group Communications
+49 152 08393540
guenther.hoerbst@trench-group.com 

The FDA Granted Orphan Drug Designation to Biostar Pharma’s Utidelone for the Treatment of Pancreatic Cancer

SAN FRANCISCO, Sept. 25, 2025 /PRNewswire/ — Biostar Pharma, Inc., the US wholly-owned subsidiary of Beijing Biostar Biopharmaceutical Co., Ltd. (“Biostar,” stock code: 2563.HK) which is a synthetic biology driven biopharma company focusing on the discovery, development and commercialization of innovative oncology drugs, is pleased to announce that its core pipeline product Utidelone has once again been granted as Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA), for the treatment of pancreatic cancer. This marks the third ODD granted to Utidelone by the FDA, following prior designations for breast cancer brain metastases and gastric cancer.

Pancreatic cancer is a highly malignant tumor known as the “king of cancers” due to its insidious early symptoms, difficulty in diagnosis, rapid progression, strong invasiveness, and poor prognosis. The five-year survival rate is only approximately 10%, far lower than that of other common cancers, making it the lowest among all malignant tumors. Currently, there is no clearly effective treatment for pancreatic cancer. Combination regimens based on gemcitabine remain the main clinical treatment, but due to the high tendency of pancreatic cancer cells to develop resistance to gemcitabine, treatment outcomes are often unsatisfactory.

The potential of Utidelone in treating pancreatic cancer has been well validated in both non-clinical and clinical studies[1]. Preclinical data show that Utidelone can significantly inhibit the proliferation and colony-forming ability of pancreatic cancer cells and exhibits strong anti-tumor activity in pancreatic cancer models. When combined with gemcitabine, Utidelone markedly reduces the IC50 value of gemcitabine without compromising its anti-tumor effect, and the combination demonstrates stronger anti-tumor activity compared with the traditional paclitaxel plus gemcitabine regimen. At the 2024 CSCO Annual Meeting, Biostar presented preliminary results from a multicenter, single-arm Phase II clinical study evaluating Utidelone combined with gemcitabine as first-line treatment for unresectable advanced pancreatic cancer. As of the report date, 20 advanced pancreatic cancer patients which were unresectable and ineligible for local treatment had been enrolled, with 11 completing their first efficacy evaluation. Among them, 3 patients achieved partial response (PR), and 5 achieved stable disease (SD); the objective response rate (ORR) was 27.27%, while the disease control rate (DCR) reached 72.72%. The median overall survival (mOS) was 9.57 months.

About Orphan Drug

An orphan drug is used to treat a rare disease that affects fewer than 200,000 patients in the US. Orphan drug development presents several major challenges including difficulties in patient recruitment, small market size and low return for the pharmaceutical companies. To encourage drug development for the benefit of rare disease patients, an ODD granted by the FDA provides many incentives such as tax relief on clinical trial costs, opportunity to apply for grants to support clinical trials, waiver of new drug application fee, acceleration for regulatory pathway, and the potential to receive 7 years of marketing exclusivity in the US market upon product approval.

About Utidelone

Utidelone is a new-generation genetically engineered microtubule inhibitor, and has similar mechanism of action with that of taxanes while demonstrating multiple advantages, including better anti-tumor activity, broader anti-tumor spectrum, better safety profile with very low hematologic toxicity, effective against multidrug-resistant tumors, less prone to developing drug resistance, capability of crossing the blood-brain barrier to prevent and treat brain tumors, and high oral bioavailability. Biostar has developed two formulations of Utidelone: injection (UTD1) and capsule (UTD2). UTD1 has been launched in China in 2021 for the treatment of metastatic breast cancer (MBC), who have progressed after at least one anthracycline- or taxane-containing chemotherapy regimen. The phase III study data showed that UTD1 plus capecitabine achieved both PFS and OS benefits versus capecitabine for heavily pretreated MBC patients, and the results were orally presented twice at ASCO annual meetings and published in prestigious journals [1-2].

About Biostar

Biostar is an integrated biopharma company focusing on the development of innovative anti-cancer drugs utilizing its synthetic biology R&D platform. The company is listed on the Hong Kong Stock Exchange (HK 2563) in 2024. We are actively selecting reliable global partners through out-licensing or co-development of Utidelone assets. We believe that our strong capabilities of R&D and manufacturing, coupled with our enriched commercial expertise, make us the preferred partner for global biopharmaceutical companies who share our goal of bringing innovative anti-cancer products to patients around the world. For additional information on partnering with Biostar, please contact our business development team at bd@biostar-pharma.com

[1] B. Xu, T. Sun, Q. Zhang, et al. Annals of Oncology, 2021, 32(2): 218-228

[2] Pin Zhang, Tao Sun, Qingyuan Zhang, et al. Lancet Oncol 2017; 18: 371-83